United Therapeutics EBITDA Margin 2012-2025 | UTHR

Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for United Therapeutics (UTHR) over the last 10 years. The current EBITDA margin for United Therapeutics as of September 30, 2025 is .
United Therapeutics EBITDA Margin Historical Data
Date TTM Revenue TTM EBITDA EBITDA Margin
2025-09-30 $3.13B $1.58B 50.37%
2025-06-30 $3.08B $1.53B 49.64%
2025-03-31 $2.99B $1.48B 49.47%
2024-12-31 $2.88B $1.45B 50.35%
2024-09-30 $2.76B $1.35B 48.82%
2024-06-30 $2.62B $1.32B 50.59%
2024-03-31 $2.50B $1.31B 52.46%
2023-12-31 $2.33B $1.24B 53.18%
2023-09-30 $2.21B $1.15B 52.29%
2023-06-30 $2.11B $1.14B 53.98%
2023-03-31 $1.98B $1.03B 51.92%
2022-12-31 $1.94B $1.03B 53.28%
2022-09-30 $1.86B $1.03B 55.11%
2022-06-30 $1.79B $0.94B 52.49%
2022-03-31 $1.77B $0.96B 54.21%
2021-12-31 $1.69B $0.61B 35.94%
2021-09-30 $1.66B $0.50B 30.31%
2021-06-30 $1.59B $0.49B 31.05%
2021-03-31 $1.51B $0.41B 27.36%
2020-12-31 $1.48B $0.64B 43.36%
2020-09-30 $1.41B $0.64B 45.49%
2020-06-30 $1.43B $0.60B 42.21%
2020-03-31 $1.44B $0.68B 47.33%
2019-12-31 $1.45B $-0.14B -9.79%
2019-09-30 $1.52B $-0.08B -5.00%
2019-06-30 $1.53B $-0.11B -7.38%
2019-03-31 $1.60B $-0.12B -7.43%
2018-12-31 $1.63B $0.84B 51.72%
2018-09-30 $1.71B $0.85B 49.47%
2018-06-30 $1.75B $1.02B 58.45%
2018-03-31 $1.75B $0.89B 51.00%
2017-12-31 $1.73B $0.85B 49.04%
2017-09-30 $1.67B $0.88B 52.78%
2017-06-30 $1.63B $0.80B 48.81%
2017-03-31 $1.60B $0.99B 62.09%
2016-12-31 $1.60B $1.09B 68.36%
2016-09-30 $1.60B $1.07B 67.34%
2016-06-30 $1.57B $1.22B 77.30%
2016-03-31 $1.51B $1.11B 73.46%
2015-12-31 $1.47B $0.73B 49.93%
2015-09-30 $1.41B $0.74B 52.74%
2015-06-30 $1.35B $0.33B 24.72%
2015-03-31 $1.33B $0.34B 25.55%
2014-12-31 $1.29B $0.57B 44.41%
2014-09-30 $1.23B $0.38B 31.11%
2014-06-30 $1.20B $0.52B 43.14%
2014-03-31 $1.16B $0.46B 39.97%
2013-12-31 $1.12B $0.34B 30.53%
2013-09-30 $1.07B $0.50B 46.27%
2013-06-30 $1.01B $0.47B 46.54%
2013-03-31 $0.96B $0.45B 47.34%
2012-12-31 $0.92B $0.46B 50.66%
2012-09-30 $0.87B $0.40B 46.14%
2012-06-30 $0.83B $0.42B 51.03%
2012-03-31 $0.79B $0.43B 54.90%
2011-12-31 $0.74B $0.36B 48.66%
2011-09-30 $0.71B $0.31B 43.94%
2011-06-30 $0.68B $0.27B 39.88%
2011-03-31 $0.63B $0.22B 34.24%
2010-12-31 $0.59B $0.21B 35.02%
2010-09-30 $0.53B $0.19B 35.78%
2010-06-30 $0.46B $0.14B 29.85%
2010-03-31 $0.41B $0.07B 16.91%
2009-12-31 $0.36B $0.06B 15.32%
2009-09-30 $0.34B $-0.08B -24.04%
2009-06-30 $0.32B $-0.08B -24.44%
2009-03-31 $0.30B $-0.06B -18.67%
2008-12-31 $0.28B $-0.06B -22.70%
2008-09-30 $0.27B $0.07B 26.32%
2008-06-30 $0.25B $0.06B 24.40%
2008-03-31 $0.23B $0.05B 19.74%
2007-12-31 $0.21B $0.02B 9.48%
2007-09-30 $0.20B $0.02B 9.64%
2007-06-30 $0.18B $0.02B 9.55%
2007-03-31 $0.17B $0.02B 12.65%
2006-12-31 $0.16B $0.03B 19.50%
2006-09-30 $0.14B $0.04B 26.57%
2006-06-30 $0.14B $0.04B 30.15%
2006-03-31 $0.13B $0.04B 32.54%
2005-12-31 $0.12B $0.05B 38.79%
2005-09-30 $0.11B $0.04B 37.96%
2005-06-30 $0.10B $0.03B 33.68%
2005-03-31 $0.08B $0.02B 28.92%
2004-12-31 $0.07B $0.02B 20.27%
2004-09-30 $0.07B $0.01B 7.58%
2004-06-30 $0.06B $0.00B -3.28%
2004-03-31 $0.06B $-0.01B -14.04%
2003-12-31 $0.05B $-0.01B -16.67%
2003-09-30 $0.05B $-0.01B -17.31%
2003-06-30 $0.04B $-0.01B -33.33%
2003-03-31 $0.04B $-0.01B -30.00%
2002-12-31 $0.03B $-0.02B -50.00%
2002-09-30 $0.02B $-0.02B -100.00%
2002-06-30 $0.02B $-0.03B -156.25%
2002-03-31 $0.01B $-0.04B -740.00%
2001-12-31 $0.01B $-0.04B -860.00%
2001-09-30 $0.00B $-0.07B -1625.00%
2001-06-30 $0.00B $-0.06B -2133.33%
2001-03-31 $0.00B $-0.08B -2733.33%
2000-12-31 $0.00B $-0.08B -4000.00%
2000-09-30 $0.00B $-0.07B -7200.00%
2000-06-30 $0.00B $-0.07B -6900.00%
2000-03-31 $0.00B $-0.05B 0.00%
1999-12-31 $0.00B $-0.04B 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $20.191B $2.877B
United Therapeutics Corporation markets four medicines in the United States to treat pulmonary arterial hypertension (PAH): Remodulin, an injectable formulation of treprostinil, Orenitram, an oral version of treprostinil, Tyvaso, an inhaled version of treprostinil, and Adcirca (tadalafil; also sold by Eli Lilly as Cialis for erectile dysfunction) tablets.
Stock Name Country Market Cap PE Ratio
Chugai Pharmaceutical (CHGCY) Japan $91.260B 34.66
Zoetis (ZTS) United States $54.668B 19.57
Takeda Pharmaceutical (TAK) Japan $51.834B 10.58
Daiichi Sankyo, - (DSNKY) Japan $37.584B 18.72
BeOne Medicines - (ONC) Switzerland $37.211B 197.28
Sandoz Group AG (SDZNY) Switzerland $35.741B 0.00
Merck (MKKGY) Germany $19.464B 12.00
Shionogi (SGIOY) Japan $16.929B 15.55
IPSEN (IPSEY) France $13.608B 0.00
Neurocrine Biosciences (NBIX) United States $13.578B 32.58
Ionis Pharmaceuticals (IONS) United States $13.004B 0.00
Summit Therapeutics (SMMT) United States $12.716B 0.00
Madrigal Pharmaceuticals (MDGL) United States $10.912B 0.00
Orion OYJ (ORINY) Finland $10.204B 29.15
Eisai (ESAIY) $8.411B 0.00
Ono Pharmaceutical (OPHLF) Japan $6.967B 21.19
Stevanato Group S.p.A (STVN) Italy $5.230B 29.27
Crinetics Pharmaceuticals (CRNX) United States $5.046B 0.00
Corcept Therapeutics (CORT) United States $4.626B 49.98
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $4.547B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $4.209B 19.99
Indivior (INDV) United States $4.122B 16.82
NewAmsterdam Pharma (NAMS) Netherlands $3.778B 0.00
Centessa Pharmaceuticals (CNTA) United Kingdom $3.397B 0.00
Hypermarcas (HYPMY) Brazil $2.977B 20.43
Catalyst Pharmaceuticals (CPRX) United States $2.898B 9.25
Dyne Therapeutics (DYN) United States $2.571B 0.00
Soleno Therapeutics (SLNO) United States $2.275B 0.00
Ocular Therapeutix (OCUL) United States $2.188B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $2.100B 0.00
Guardian Pharmacy Services (GRDN) United States $1.932B 37.21
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.916B 22.70
Ardelyx (ARDX) United States $1.888B 0.00
Amylyx Pharmaceuticals (AMLX) United States $1.731B 0.00
Oruka Therapeutics (ORKA) United States $1.665B 0.00
Harrow (HROW) United States $1.647B 101.07
Enliven Therapeutics (ELVN) United States $1.530B 0.00
Collegium Pharmaceutical (COLL) United States $1.438B 7.12
BioCryst Pharmaceuticals (BCRX) United States $1.431B 84.88
Relay Therapeutics (RLAY) United States $1.288B 0.00
Evotec AG (EVO) Germany $1.282B 0.00
Xeris Biopharma Holdings (XERS) United States $1.234B 0.00
Savara (SVRA) United States $1.225B 0.00
Aktis Oncology (AKTS) United States $1.097B 0.00
Cronos Group (CRON) Canada $1.061B 0.00
Theravance Biopharma (TBPH) United States $1.026B 43.06
ARS Pharmaceuticals (SPRY) United States $1.009B 0.00
Xencor (XNCR) United States $0.913B 0.00
Ironwood Pharmaceuticals (IRWD) United States $0.851B 20.12
KalVista Pharmaceuticals (KALV) United States $0.810B 0.00
Nektar Therapeutics (NKTR) United States $0.755B 0.00
Esperion Therapeutics (ESPR) United States $0.751B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.671B 5.99
Bioventus (BVS) United States $0.664B 13.59
ProKidney (PROK) United States $0.653B 0.00
Altimmune (ALT) United States $0.574B 0.00
Lexeo Therapeutics (LXEO) United States $0.547B 0.00
Lyell Immunopharma (LYEL) United States $0.537B 0.00
Zevra Therapeutics (ZVRA) United States $0.505B 0.00
Organogenesis (ORGO) United States $0.498B 0.00
Aclaris Therapeutics (ACRS) United States $0.488B 0.00
Elite Pharmaceuticals (ELTP) United States $0.487B 0.00
Siga Technologies (SIGA) United States $0.476B 6.51
4D Molecular Therapeutics (FDMT) United States $0.455B 0.00
Nature's Sunshine Products (NATR) United States $0.432B 25.70
USANA Health Sciences (USNA) United States $0.412B 11.49
Aquestive Therapeutics (AQST) United States $0.395B 0.00
Cybin (HELP) Canada $0.376B 0.00
Akebia Therapeutics (AKBA) United States $0.361B 0.00
Protara Therapeutics (TARA) United States $0.320B 0.00
Aldeyra Therapeutics (ALDX) United States $0.312B 0.00
Larimar Therapeutics (LRMR) United States $0.305B 0.00
Achieve Life Sciences (ACHV) Canada $0.298B 0.00
Avalo Therapeutics (AVTX) United States $0.292B 0.00
Profound Medical (PROF) Canada $0.289B 0.00
Fractyl Health (GUTS) United States $0.286B 0.00
Relmada Therapeutics (RLMD) United States $0.286B 0.00
OmniAb (OABI) United States $0.282B 0.00
Silence Therapeutics (SLN) United Kingdom $0.268B 0.00
Heron Therapeutics (HRTX) United States $0.260B 0.00
Enlivex Therapeutics (ENLV) Israel $0.256B 0.00
Journey Medical (DERM) United States $0.236B 0.00
MediWound (MDWD) Israel $0.227B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.223B 0.00
Galectin Therapeutics (GALT) United States $0.213B 0.00
Century Therapeutics (IPSC) United States $0.212B 0.00
AleAnna (ANNA) United States $0.192B 0.00
Innate Pharma SA (IPHYF) France $0.181B 0.00
Minerva Neurosciences (NERV) United States $0.172B 0.00
Surrozen (SRZN) United States $0.168B 0.00
Context Therapeutics (CNTX) United States $0.166B 0.00
Procaps Group, S.A (PROCF) Luxembourg $0.161B 0.00
VAXART, INC (VXRT) United States $0.161B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.153B 0.00
Unicycive Therapeutics (UNCY) United States $0.149B 0.00
Avita Medical (RCEL) United States $0.135B 0.00
Inhibikase Therapeutics (IKT) United States $0.131B 0.00
Prelude Therapeutics (PRLD) United States $0.127B 0.00
Karyopharm Therapeutics (KPTI) United States $0.121B 0.00
Incannex Healthcare (IXHL) Australia $0.119B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.119B 0.00
Vivani Medical (VANI) United States $0.108B 0.00
Cassava Sciences (SAVA) United States $0.106B 0.00
Cardiol Therapeutics (CRDL) Canada $0.104B 0.00
Pyxis Oncology (PYXS) United States $0.101B 0.00
Korro Bio (KRRO) United States $0.101B 0.00
Champions Oncology (CSBR) United States $0.094B 39.71
Gain Therapeutics (GANX) United States $0.079B 0.00
PolyPid (PYPD) Israel $0.076B 0.00
Assertio Holdings (ASRT) United States $0.074B 0.00
Dominari Holdings (DOMH) United States $0.068B 0.00
Acrivon Therapeutics (ACRV) United States $0.065B 0.00
NRx Pharmaceuticals (NRXP) United States $0.064B 0.00
Metagenomi Therapeutics (MGX) United States $0.063B 0.00
Rafael Holdings (RFL) United States $0.063B 0.00
PMV Pharmaceuticals (PMVP) United States $0.062B 0.00
Arch Biopartners (ACHFF) Canada $0.061B 0.00
Lipocine (LPCN) United States $0.061B 0.00
ElectroCore (ECOR) United States $0.060B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.059B 49.13
Nutriband (NTRB) United States $0.058B 0.00
Lite Strategy (LITS) United States $0.047B 0.00
Talphera (TLPH) United States $0.047B 0.00
Telomir Pharmaceuticals (TELO) United States $0.046B 0.00
FibroGen (FGEN) United States $0.039B 0.00
Plus Therapeutics (PSTV) United States $0.038B 0.00
Reviva Pharmaceuticals Holdings (RVPH) United States $0.038B 0.00
Wellgistics Health (WGRX) United States $0.036B 0.00
Mural Oncology (MURA) Ireland $0.035B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.035B 0.00
SCYNEXIS (SCYX) United States $0.035B 0.00
Jupiter Neurosciences (JUNS) United States $0.031B 0.00
TherapeuticsMD (TXMD) United States $0.030B 0.00
Natural Alternatives (NAII) United States $0.026B 0.00
Klotho Neurosciences (KLTO) United States $0.024B 0.00
Liminatus Pharma (LIMN) United States $0.021B 0.00
Scienture Holdings (SCNX) United States $0.021B 0.00
Iterum Therapeutics (ITRM) Ireland $0.019B 0.00
Traws Pharma (TRAW) United States $0.019B 0.02
VYNE Therapeutics (VYNE) United States $0.019B 0.00
Inotiv (NOTV) United States $0.019B 0.00
Cosmos Health (COSM) United States $0.019B 0.00
Vyome Holdings (HIND) United States $0.018B 0.00
Citius Pharmaceuticals (CTXR) United States $0.018B 0.00
Vivos Therapeutics (VVOS) United States $0.017B 0.00
Tempest Therapeutics (TPST) United States $0.015B 0.00
Mannatech (MTEX) United States $0.015B 0.00
BioLineRx (BLRX) Israel $0.013B 0.00
CASI Pharmaceuticals (CASI) China $0.012B 0.00
Phio Pharmaceuticals (PHIO) United States $0.012B 0.00
Curanex Pharmaceuticals Inc (CURX) United States $0.010B 0.00
China SXT Pharmaceuticals (SXTC) China $0.010B 0.00
Addex Therapeutics (ADXN) Switzerland $0.010B 0.00
Nuvilex (PMCB) United States $0.010B 0.00
Ernexa Therapeutics (ERNA) United States $0.009B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.009B 0.00
BioVie (BIVI) United States $0.009B 0.00
TransCode Therapeutics (RNAZ) United States $0.009B 0.00
Ainos (AIMD) United States $0.009B 0.00
Mangoceuticals (MGRX) United States $0.008B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.008B 0.00
Kiora Pharmaceuticals (KPRX) United States $0.008B 0.00
Biomerica (BMRA) United States $0.008B 0.00
Heatwurx (PCSA) United States $0.007B 0.00
Redhill Biopharma (RDHL) Israel $0.007B 0.00
Alaunos Therapeutics (TCRT) United States $0.007B 0.00
Aptorum Group (APM) United Kingdom $0.006B 0.00
Indaptus Therapeutics (INDP) United States $0.006B 0.00
Xenetic Biosciences (XBIO) United States $0.006B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.006B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.005B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.005B 0.00
Clearmind Medicine (CMND) Canada $0.004B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.004B 0.00
XORTX Therapeutics (XRTX) Canada $0.004B 0.00
Lyra Therapeutics (LYRA) United States $0.004B 0.00
InMed Pharmaceuticals (INM) Canada $0.003B 0.00
Jaguar Animal Health (JAGX) United States $0.003B 0.00
Universe Pharmaceuticals INC (UPC) China $0.002B 0.00
CDT Equity (CDT) United States $0.002B 0.00
PainReform (PRFX) Israel $0.002B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.001B 0.00
Aditxt (ADTX) United States $0.001B 0.00
SciSparc (SPRC) Israel $0.001B 0.00
Emisphere Technologies (EMIS) United States $0.000B 0.00
Grifols, S.A (GRFS) Spain $0.000B 0.00
4D Pharma (LBPS) United Kingdom $0.000B 0.00
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00